Pls refer the attachment

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

VIJAYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.5%Reaction day

₹1208.00

prior close

₹1269.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%+5.4% vs market

Healthcare Service Provider peers, median of 27sector+1.5%+4.1% vs sector

On the reaction day the stock moved 5.4 pts more than Nifty Smallcap 250 and 4.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.4

10m

-2.7

15m

-2.5

30m

-2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.5+0.2+5.4+1.5+4.1

Next day

+10.1-0.9+11.0+1.6+8.5

+6.0-3.9+9.9-0.2+6.2

+7.0-3.6+10.6+0.0+7.0

+6.0-3.6+9.5+1.2+4.8

+11.3-3.9+15.2-0.5+11.8

+8.0-4.3+12.3-0.2+8.2

15d

+3.4-3.2+6.6+0.7+2.7

+8.1-3.8+11.9-1.0+9.1

+10.1+1.1+9.0-3.1+13.2

+15.5+5.4+10.2-3.6+19.2

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 27Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vijaya Diagnostic Centre reported strong Q4 FY26 results with its highest-ever quarterly revenue of Rs 219.4 crore, up 26.6% YoY. Full-year FY26 revenue crossed Rs 800 crore at Rs 814.2 crore, growing 19.5% YoY and delivering a 16.5% CAGR over five years since listing. EBITDA grew 38.7% YoY in Q4 to Rs 95.5 crore with margins expanding by 379 basis points to 43.5%, while PAT rose 37.5% to Rs 47.9 crore. Volume growth was broad-based with total tests up 18.5% and footfall up 15.8% in Q4. The company plans to add 4-5 hubs and 10-12 spokes in FY27 along with a fully automated laboratory in Hyderabad.

Likely market impact

Strong quarterly performance with margin expansion and robust volume growth signals healthy execution and market share gains, which should be positive for the stock given the company's outperformance versus its 15% long-term revenue guidance.